| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLC25A4 |
| Uniprot No | P12235 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-298 aa |
| 活性数据 | GDHAWSFLKDFLAGGVAVSKTAVAPIERVKLLLQVQHASKQISAEKQYKGIIDCVVRIPKEQGFLSFWRGNLANVIRYFPTQALNFAFKDKYKQLFLGGVDRHKQFWRYFAGNLASGGGATSLCFVYPLDFARTRLDVGKGQREFHGLGDCIIKIFKSDGLRGLYQGFNVSVQGIIIYRYFGVYDTAKGMLPDPKNVHIFVSWMIAQSVTAVAGLVSYPFDTVRRRMMMQSGRKGADIMYTGTVDCWRKIAKDEGAKAFFKGAWSNVLRGMGGAFVLVLYDEIKKYV |
| 分子量 | 34.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4条关于重组人SLC25A4(ANT1)蛋白的参考文献及其摘要概括：
1. **文献名称**: *"Structure of the human mitochondrial ADP/ATP carrier SLC25A4 in complex with carboxyatractyloside"*
**作者**: Lee et al.
**摘要**: 该研究通过冷冻电镜解析了人源SLC25A4(ANT1)与抑制剂羧基苍术苷(CATR)结合的复合体结构，揭示了ANT1蛋白的构象变化及ADP/ATP转运的分子机制，为线粒体能量代谢相关疾病提供了结构基础。
2. **文献名称**: *"Pathogenic mutations in the mitochondrial ADP/ATP translocase SLC25A4 alter energy metabolism and mitochondrial dynamics"*
**作者**: Smith et al.
**摘要**: 研究发现SLC25A4基因突变(如A114P)通过破坏ADP/ATP交换功能导致线粒体能量代谢异常，并诱导线粒体过度分裂，从而引发进行性外眼肌麻痹(PEO)和心肌病等疾病。
3. **文献名称**: *"Functional reconstitution of recombinant SLC25A4 into proteoliposomes reveals impaired transport capacity in disease-associated variants"*
**作者**: Garcia et al.
**摘要**: 通过将重组表达的人SLC25A4蛋白重构至脂质体中，验证了其ADP/ATP转运活性，并证明致病突变(如D104G)显著降低转运效率，阐明了分子水平的功能缺陷机制。
4. **文献名称**: *"SLC25A4 as a potential therapeutic target in cancer: Role in apoptosis and chemoresistance"*
**作者**: Chen et al.
**摘要**: 综述了ANT1在线粒体凋亡通路中的作用，指出其过表达可通过释放细胞色素c增强化疗敏感性，并提出靶向SLC25A4可能成为克服肿瘤耐药性的新策略。
注：以上文献名为示意性概括，实际需根据具体论文调整。建议通过PubMed或Google Scholar以“SLC25A4”“ANT1”“recombinant”等关键词查找最新研究。
The human SLC25A4 protein, also known as the adenine nucleotide translocator 1 (ANT1), is a mitochondrial inner membrane transporter critical for cellular energy metabolism. As a member of the solute carrier family 25 (SLC25), it facilitates the exchange of cytosolic ADP and mitochondrial ATP, maintaining the adenosine nucleotide pool essential for oxidative phosphorylation. Structurally, it comprises three homologous domains, each with two transmembrane α-helices, forming a gated pore regulated by membrane potential and substrate availability.
ANT1 dysfunction is linked to mitochondrial disorders, including autosomal dominant progressive external ophthalmoplegia (AD-PEO) and hypertrophic cardiomyopathy, often caused by mutations disrupting nucleotide transport or membrane integrity. Its role extends beyond energy transduction; ANT1 participates in mitochondrial permeability transition pore (mPTP) formation, a key event in apoptosis, linking it to neurodegenerative diseases and ischemia-reperfusion injury.
Recombinant SLC25A4 proteins are engineered for functional studies, typically expressed in E. coli or mammalian systems. These tools enable structural analysis (e.g., cryo-EM studies), drug screening for mPTP inhibitors, and disease modeling. Recent research explores its interactions with viral proteins and cancer chemoresistance, highlighting therapeutic potential. However, challenges remain in recapitulating native membrane lipid interactions in vitro, necessitating advanced reconstitution methods for mechanistic insights.
×
